Payment overview · 2025
General Payments
$339.85
18 reported records · 10 companies
Healthcare provider profile · identity verified
Blake Putman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CARO, MI · NPI 1659784338
Verified facts
What the public records show
CMS Open Payments records show Blake Putman, M.D. received $339.85 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.15 | 15.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.77 | 15.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.03 | 15.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.35 | 12.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.61 | 10.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.78 | 7.9% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $21.80 | 6.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.63 | 6.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.52 | 5.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.21 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $339.85 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $72.66 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.15 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.77 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.92 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
118 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
124 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 478 | 164 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 446 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 313 | 90 |
| Omeprazole | Omeprazole | 313 | 113 |
| Metformin Hcl | Metformin Hcl | 282 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 259 | 90 |
| Lisinopril | Lisinopril | 259 | 81 |
| Gabapentin | Gabapentin | 258 | 67 |
| Prednisone | Prednisone | 221 | 145 |
| Glipizide | Glipizide | 198 | 55 |
| Alprazolam | Alprazolam | 195 | 44 |
| Tramadol Hcl | Tramadol Hcl | 175 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 40 |
| Eliquis | Apixaban | 144 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 58 |
| Trazodone Hcl | Trazodone Hcl | 141 | 57 |
| Losartan Potassium | Losartan Potassium | 135 | 50 |
| Famotidine | Famotidine | 133 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 130 | 17 |
| Simvastatin | Simvastatin | 129 | 39 |
| Ozempic | Semaglutide | 124 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 45 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 120 | 29 |
| Furosemide | Furosemide | 118 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 43 |
| Celecoxib | Celecoxib | 111 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 49 |
| Baclofen | Baclofen | 102 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 35 |
| Meloxicam | Meloxicam | 102 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 37 |
| Pregabalin | Pregabalin | 97 | 18 |
| Trulicity | Dulaglutide | 96 | 21 |
| Montelukast Sodium | Montelukast Sodium | 88 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 33 |
| Carvedilol | Carvedilol | 84 | 24 |
| Potassium Chloride | Potassium Chloride | 83 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 19 |
| Sertraline Hcl | Sertraline Hcl | 80 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 27 |
| Azithromycin | Azithromycin | 72 | 56 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 26 |
| Clonazepam | Clonazepam | 59 | suppressed |
| Topiramate | Topiramate | 57 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 16 |
| Lorazepam | Lorazepam | 49 | 16 |
| Donepezil Hcl | Donepezil Hcl | 48 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 11 |
| Allopurinol | Allopurinol | 47 | 18 |
| Spironolactone | Spironolactone | 46 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 13 |
| Atenolol | Atenolol | 45 | 14 |
| Fluconazole | Fluconazole | 44 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 13 |
| Ondansetron Odt | Ondansetron | 43 | 17 |
| Ibuprofen | Ibuprofen | 41 | 15 |
| Bumetanide | Bumetanide | 40 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | 16 |
| Ezetimibe | Ezetimibe | 38 | 19 |
| Lovastatin | Lovastatin | 38 | 11 |
| Diazepam | Diazepam | 36 | 12 |
| Glimepiride | Glimepiride | 36 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 29 |
| Naproxen | Naproxen | 34 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | 15 |
| Jardiance | Empagliflozin | 31 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 26 |
| Nifedipine Er | Nifedipine | 30 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 29 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | 12 |
| Cephalexin | Cephalexin | 27 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 22 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $339.85 · 18 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, INSPIRE, REXULTI, TRELEGY ELLIPTA, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error